Drug Trial Radar · NCT01594515
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
May 2012
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 9, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
In this first-in-man trial, safety, tolerability, pharmacokinetics, and selected pharmacodynamics parameters of BI 1015550 will be assessed in healthy male volunteers.
Conditions
- Healthy
Interventions
BI 1015550Drug
High dose powder for oral solution
BI 1015550Drug
Medium dose powder for oral solution
BI 1015550Drug
Low dose powder for oral solution
BI 1015550Drug
Low dose powder for oral solution
BI 1015550Drug
Low dose powder for oral solution
PlaceboDrug
Solution for oral administration
BI 101550Drug
High dose powder for oral solution
BI 1015550Drug
Low dose powder for oral solution
BI 1015550Drug
Medium dose powder for oral solution
BI 1015550Drug
Medium dose powder for oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number (%) of Subjects With Drug Related Adverse EventsTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
- Number (%) of Subjects With Clinically Relevant Abnormalities in Clinical Laboratory TestsTime frame: Day -21 to -2, upto -72 hours, 4h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
- Number (%) of Subjects With Clinically Relevant Abnormalities in Vital SignsTime frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
- Number (%) of Subjects With Clinically Relevant Abnormalities in 12-lead ECGsTime frame: Day -21 to -2, -1 hour, 0.5h, 1h, 2h, 4h, 8h, 10h, 24h, 48h, 72h and study examination(within 5 to 7 days after last PK sampling).
- Number (%) of Subjects With Clinically Relevant Abnormalities in TolerabilityTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
- Number (%) of Subjects With Clinically Relevant Abnormalities in Physical ExaminationsTime frame: From the day of informed consent(-21 days) until the end-of-study examination(within 5 to 7 days after last PK sampling), upto 10 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1305.1.1 Boehringer Ingelheim Investigational Site
Ingelheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.